Auriga Comments On United Therapeutics Top-Line Results

According to Auriga, United Therapeutics UTHR reported preliminary top-line results from the closely watched FREEDOM-M trial. Auriga said that the primary endpoint was change in 6 Minute Walk Distance (6MWD) at 12 weeks for 228 patients that received 0.25 mg dose increments. “Results showed patients on oral Remodulin improved their median 6MWD by approximately 23 meters (p=0.0125). While the trial clearly met the pre-specified endpoints with a high degree of statistical significance, the magnitude of the 6MWT difference (23M) was not as large as we or the street was expecting (30 to 40M).” United Therapeutics closed yesterday at $59.00.